Bio-Path Holdings, Inc. (NASDAQ:BPTH) Sees Large Decline in Short Interest

Bio-Path Holdings, Inc. (NASDAQ:BPTH) was the recipient of a significant drop in short interest during the month of October. As of October 31st, there was short interest totalling 77,800 shares, a drop of 80.0% from the October 15th total of 388,600 shares. Currently, 2.1% of the shares of the stock are short sold. Based on an average daily trading volume, of 1,410,000 shares, the short-interest ratio is presently 0.1 days.

Wall Street Analyst Weigh In

Separately, StockNews.com initiated coverage on shares of Bio-Path in a report on Friday. They issued a “sell” rating on the stock.

Hedge Funds Weigh In On Bio-Path

A hedge fund recently bought a new stake in Bio-Path stock. Armistice Capital LLC purchased a new position in shares of Bio-Path Holdings, Inc. (NASDAQ:BPTH) in the 2nd quarter, according to the company in its most recent filing with the SEC. The institutional investor purchased 97,000 shares of the company’s stock, valued at approximately $194,000. Armistice Capital LLC owned 4.66% of Bio-Path as of its most recent filing with the SEC. 5.74% of the stock is owned by institutional investors and hedge funds.

Bio-Path Trading Down 3.2 %

Shares of NASDAQ BPTH traded down $0.03 on Tuesday, reaching $0.87. 30,121 shares of the company traded hands, compared to its average volume of 1,154,581. The company has a 50 day moving average of $0.99 and a 200 day moving average of $1.63. Bio-Path has a fifty-two week low of $0.80 and a fifty-two week high of $12.40.

Bio-Path (NASDAQ:BPTH) last issued its quarterly earnings results on Thursday, August 15th. The company reported ($1.16) EPS for the quarter, beating analysts’ consensus estimates of ($1.54) by $0.38. During the same period last year, the business earned ($10.60) EPS. As a group, equities analysts predict that Bio-Path will post -6.2 earnings per share for the current year.

About Bio-Path

Bio-Path Holdings, Inc operates as a clinical and preclinical stage oncology focused RNAi nanoparticle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction.